NEW YORK, May 23, 2017 /PRNewswire/ --
Stock-Callers.com has initiated coverage on Ophthotech Corp. (NASDAQ: OPHT), Pacific Biosciences of California Inc. (NASDAQ: PACB), PTC Therapeutics Inc. (NASDAQ: PTCT), and Portola Pharmaceuticals Inc. (NASDAQ: PTLA). The Biotech arena includes companies, which produce medicines that have a biological basis. These firms also have high costs due to their focus on R&D as well as the length of time and difficulty in testing and creating new products. Learn more about these stocks by downloading their comprehensive and free reports at:
On Monday, shares in New York headquartered Ophthotech Corp. rose 2.03%, ending the day at $2.51. The stock recorded a trading volume of 698,249 shares. The Company's shares are trading below their 50-day moving average by 18.44%. Moreover, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have a Relative Strength Index (RSI) of 35.77.
On May 03rd, 2017, Ophthotech announced financial and operating results for Q1 ended March 31st, 2017. Collaboration revenue was $1.7 million for the quarter; R&D expenses were $32 million; general and administrative expenses were $13.2 million; and net loss was $43.1 million. The Company also had $227.6 million in cash, cash equivalents, and marketable securities as of March 31st, 2017. OPHT complete research report is just a click away and free at:
Pacific Biosciences of California
Shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. ended the day 1.79% lower at $3.83 with a total trading volume of 590,767 shares. Since the start of this year, the stock has gained 0.79% The Company's shares are trading below their 50-day moving average by 16.80%. Furthermore, shares of Pacific Biosciences of California, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 35.01.
On April 26th, 2017, the Company announced financial results for its Q1 ended March 31st, 2017. Product and service revenue for the quarter was $24.9 million; gross profit was $8.9 million, resulting in a gross margin of 35.9%; operating expenses totaled $32.2 million; and net loss was $23.9 million. Additionally, cash, cash equivalents, and investments, excluding restricted cash, totaled $56.1 million at March 31st, 2017. The complimentary report on PACB can be downloaded at:
At the close of trading on Monday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. finished 1.40% lower at $13.41 with a total trading volume of 557,609 shares. The stock has advanced 17.94% in the last one month and 22.91% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 23.60% and 23.64%, respectively. Additionally, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 68.85.
On May 19th, 2017, PTC Therapeutics announced that on May 17th, 2017, it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten, new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the Company's new hires' employment compensation. Sign up for your complimentary research report on PTCT at:
South San Francisco, California headquartered Portola Pharmaceuticals Inc.'s shares recorded a trading volume of 423,433 shares at the end of yesterday's session. The stock closed the day 1.16% lower at $38.43. The Company's shares have advanced 0.60% in the past month, 17.67% in the previous three months, and 71.26% on an YTD basis. The stock is trading above its 200-day moving average by 40.38%. Additionally, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 43.52.
On May 18th, 2017, Portola Pharma announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association, to be held from June 22nd, 2017 to June 25th, 2017 in Madrid, Spain. Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Get free access to your research report on PTLA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA